Skip to main content
. 2024 Aug 19;30(Suppl):S5–S105. doi: 10.3350/cmh.2024.0506

Figure 7.

Figure 7.

Algorithm for screening high-risk groups of patients with nonalcoholic fatty liver disease. T2DM, type 2 diabetes mellitus; HBV, hepatitis B virus; HCV, hepatitis C virus; FIB-4, fibrosis-4 index; VCTE, vibration-controlled transient elastography; LS, liver stiffness; MRE, magnetic resonance elastography; ELF, enhanced liver fibrosis; NITs, non-invasive tests.